Related Experiment Video

Updated: Jul 5, 2026

Automation of Bio-Atomic Force Microscope Measurements on Hundreds of C. albicans Cells
09:27

Automation of Bio-Atomic Force Microscope Measurements on Hundreds of C. albicans Cells

Published on: April 2, 2021

Micafungin in pediatrics: when one size does not fit all

Negar Ashouri1, Jasjit Singh, Antonio Arrieta

  • 1Children's Hospital of Orange County, Division of Infectious Diseases, 455 South Main Street, Orange, CA 92868, USA. nashouri@choc.org

Expert Opinion on Drug Metabolism & Toxicology
|April 25, 2008
PubMed

Insights

Micafungin, an echinocandin antifungal, is effective against Candida and Aspergillus infections. Understanding its pediatric pharmacokinetics is crucial for optimizing treatment in children.

Area of Science:

  • Pharmacology
  • Mycology
  • Pediatric Medicine

Background:

  • Micafungin is an FDA-approved echinocandin antifungal targeting 1,3-beta-D-glucan.
  • It demonstrates efficacy against invasive Candida and Aspergillus infections.
  • Its favorable safety profile makes it a key treatment option.

Purpose of the Study:

  • To review micafungin's use in pediatric populations.
  • To highlight differences in pediatric pharmacokinetics compared to adults.
  • To emphasize the need for optimized pediatric treatment strategies.

Main Methods:

  • Literature review of published studies on micafungin in pediatric patients.
  • Analysis of pharmacokinetic data from pediatric and adult studies.
  • Synthesis of findings to inform clinical practice.

Main Results:

  • Pediatric pharmacokinetic profiles of micafungin differ from adult profiles.
  • Studies indicate variability in drug exposure within the pediatric population.
  • Existing data underscore the need for age- and weight-specific dosing considerations.

Conclusions:

  • Optimizing micafungin treatment in pediatric patients requires understanding unique pharmacokinetic characteristics.
  • Further research may be needed to refine dosing guidelines for diverse pediatric age groups.
  • Ensuring appropriate micafungin dosing is essential for effective treatment of pediatric fungal infections.

More Related Videos

Size Matters: Measurement of Capsule Diameter in Cryptococcus neoformans08:24

Size Matters: Measurement of Capsule Diameter in Cryptococcus neoformans

Published on: February 27, 2018

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations01:15

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...